Source-grounded facts extracted from BIOLIFE SOLUTIONS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIOLIFE SOLUTIONS INC reported the three months ended March 31, 2026 results: revenue $27.5 million, net income $1.2 million, EPS $0.02. Guidance reaffirmed.
“BioLife Solutions Reports First Quarter 2026 Financial Results Total revenue of $27.5 million, up 25% over Q1 2025 GAAP gross margin and non-GAAP adjusted gross margin of 64% GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of revenue”
Catherine Coste was appointed as Director and Audit Committee Chair at BIOLIFE SOLUTIONS INC.
“Effective March 18, 2025, the board of directors (the “Board”) of BioLife Solutions, Inc. (the “Company”) appointed Catherine Coste to serve as a member of the Board until the Company’s 2025 Annual Meeting of Stockholders”
BIOLIFE SOLUTIONS INC reported first quarter ended March 31, 2024 results: revenue $31.7 million, net income $10.2 million, EPS $0.22. Guidance reaffirmed.
“51 % Adjusted Gross Margin 53 % Net Loss $ (4,453) Adjusted EBITDA $ 3,583 Adjusted EBITDA as a % of Revenue 13 % REVENUE • Total revenue for the first quarter of 2024 was $31.7 million, a decrease of $6.0 million, or 16%, from $37.7 million for the first quarter of 2023 and down $1.0 million, or 3%, sequentially from the fourth quarter of 2023. ◦ Cell”
BIOLIFE SOLUTIONS INC completed a disposition involving GCI Holdings Company, LLC for $1.00 (closed 2024-04-17).
“tock Purchase Agreement for Global Cooling Divestiture On April 17, 2024, BioLife Solutions, Inc., a Delaware corporation (the “Company”), entered into a Stock Purchase Agreement, dated April 17, 2024 (the “Purchase Agreement”), by and between the Company and GCI Holdings Company, LLC, an Ohio limited liability company that is wholly owned by an employee of Global Cooling (as defined below) (“Buyer”), for the sale of all of the issued and outstanding shares of common stock (the “Shares”) of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Global Cooling”), to Buyer for an aggregate purchase price of $1.00 (the “Transaction”).”
BIOLIFE SOLUTIONS INC entered into Consent and Second Amendment to Loan and Security Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (effective 2024-04-17).
“On April 17, 2024, the Company entered into a Consent and Second Amendment to Loan and Security Agreement, dated April 17, 2024 (the “Amendment”), by and among Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”), the Company, SAVSU Technologies, Inc., a Delaware corporation (“SAVSU”), Arctic Solutions, Inc., a Delaware corporation doing business as Custom Biogenic Systems (“Arctic”), SciSafe Holdings, Inc., a Delaware corporation (“SciSafe”), Global Cooling, and Sexton Biotechnologies, Inc., a Delaware corporation (“Sexton,” and together with the Company, SAVSU, Arctic, SciSafe, and Global Cooling, “Borrower”).”
BIOLIFE SOLUTIONS INC entered into Stock Purchase Agreement with GCI Holdings Company, LLC valued at $1.00 (effective 2024-04-17).
“on April 17, 2024, BioLife Solutions, Inc., a Delaware corporation (the “Company”), entered into a Stock Purchase Agreement, dated April 17, 2024 (the “Purchase Agreement”), by and between the Company and GCI Holdings Company, LLC, an Ohio limited liability company that is wholly owned by an employee of Global Cooling (as defined below) (“Buyer”), for the sale of all of the issued and outstanding shares of common stock (the “Shares”) of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Global Cooling”), to Buyer for an aggregate purchase price of $1.00 (the “Transaction”).”
BIOLIFE SOLUTIONS INC announced a restructuring with charges of approximately $2.5 million of charges affecting Global Cooling, Inc. (approximately 47 employees (representing approximately 11% of its full-time employees)).
“on March 29, 2024, and all affected employees were informed on April 17, 2024, following the execution of the Purchase Agreement. The Company expects to recognize approximately $2.5 million of charges in connection with the RIF, comprised of approximately $2.0 million of stock compensation expense and approximately $0.5 million in cash expenditures, substantially”
BIOLIFE SOLUTIONS INC updated its the fourth quarter and year ended December 31, 2023 guidance (initiated).
“On February 29, 2024, BioLife Solutions, Inc., a Delaware corporation, issued a press release announcing financial results and operational highlights for the fourth quarter and year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.